Estrogen receptor, progesterone receptor, and nuclear size features in female breast cancer in Libya: Correlation with clinical features and survival

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3485-3493

  Abdalla, Fathi B Elmabrouk ^a,b   Markus, Rabia ^c   Buhmeida, Abdelbaset ^d   Boder, Jamela ^a,b   Syrjänen, Kari ^a   Collan, Yrjö ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b National Cancer Institute   (Libyan Arab Jamahiriya)

^c Tripoli Medical Center   (Libyan Arab Jamahiriya)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Clinical features; Estrogen receptor (ER); Histopathology; Hormonal receptor (HR); Libyan female breast carcinoma; Nuclear morphometry; Progesterone receptor (PR); Survival

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIBYAN ARAB JAMAHIRIYA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORPHOMETRICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

BREAST NEOPLASMS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIBYA; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 84865697714     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Curado MP: Breast cancer in the world: incidence and mortality. Salud publica de Mexico 53: 372-384, 2011.
2. Singh R and Al-Sudani OE: Cancer mortality in Benghazi, Libyan Arab Jamahiriya, 1991-96. East Mediterr Health J 7: 255-273, 2001.
3. Adesunkanmi AR, Lawal OO, Adelusola KA and Durosimi MA: The severity, outcome and challenges of breast cancer in Nigeria. Breast 15: 399-409, 2006.
4. Ikpatt F: Nigerian breast cancer: Prognostic value of histomorpho- metry. Turku: Ann Univ Turku 487: 1-128, 2002.
5. Abdalla F, Boder J, Buhmeida A, Hashmi H, Elzagheid A and Collan Y: Nuclear morphometry in FNABs of breast disease in Libyans. Anticancer Res 28: 3985-3989, 2008.
6. Elzagheid A: Application of E-cadherin immunostaining, morphometry and DNA cytometry in the diagnosis and prognosis of the breast lesions. Turku: Ann Univ Turku 586: 1-108, 2003.
7. Barbareschi M and Doglioni C: The immunohistochemical detection of steroid hormone receptors in breast cancer: open problems and new perspectives. Pathologica 94: 115-120, 2002.
8. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P and Dickman PW: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case control study. Breast Cancer Res 8: R11, 2006.
9. Kurosumi M: Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer. Breast Cancer 14: 189-193, 2007.
10. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
11. MacMahon B: Epidemiology and the causes of breast cancer. Int J Cancer 118: 2373-2378, 2006.
12. Jobling MA, Hurles M and Tyler-Smith C: Human Evolutionary Genetics: Origin, Peoples and Disease. Garland Science, Taylor and Francis group: New York 2004.
13. Ikpatt F and Olopade O: Genetics of Breast cancer in women of African descent: An overview in: Breast Cancer in Women of African Descent. Wiliams C, Olopade O and Falkson C (eds.). Springer, p. 23-38, 2006.
14. Singletary SE: Rating the risk factors for breast cancer. Ann Surg 237: 474-482, 2003.
15. Boder J, Abdalla F, Elfageih M, Abusaa A, Alfagieh M, Buhmeida A and Collan Y: Breast cancer patients in Libya: Comparison with European and central African patients. Oncol Lett 2: 323-330, 2011.
16. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP and Colditz GA: Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24: 1342-1349, 2006.
17. Whitworth A: New research suggests access, genetic differences play role in high minority cancer death rate. J Natl Cancer Inst 98: 669, 2006.
18. Abdalla F, Boder J, Markus R, Hashmi H, Buhmeida A and Collan Y: Correlation of nuclear morphometry of breast cancer in histological sections with clinicopathological features and prognosis. Anticancer Res 29: 1771-1776, 2009.
19. Baak JP, Van Dop H, Kurver PH and Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer 56: 374-382, 1985.
20. Elzagheid A, Kuopio T, Pyrhonen S and Collan Y: Lymph node status as a guide to selection of available prognostic markers in breast cancer: The clinical practice of the future? Diagn Pathol 1: 41, 2006.
21. Zajdela A, De LaRiva LS and Ghossein NA: The relation of prognosis to the nuclear diameter of breast cancer cells obtained by cytologic aspiration. Acta Cytol 23: 75-80, 1979.
22. Tosi P, Luzi P, Sforza V, Santopietro R, Bindi MTucci E, Barbini P and Baak JP: Correlation between morphometrical parameters and disease-free survival in ductal breast cancer treated only by surgery. Appl Pathol 4: 33-42, 1986.
23. Kronqvist P, Kuopio T and Collan Y: Morphometric grading of invasive ductal breast cancer. I. Thresholds for nuclear grade. Br J Cancer 78: 800-805, 1998.
24. Larsimont D, Kiss R, d'Olne D, de Launoit Y, Mattheiem W, Paridaens R, Pasteels JL and Gompel C: Correlation between nuclear cytomorphometric parameters and estrogen receptor levels in breast cancer. Cancer 63: 2162-2168, 1989.
25. Giardina C, Serio G, Simone G, Pennella A, Vacca E, Ricco R, Scordari D and Pesce Delfino V: Nuclear morphometry and estrogen receptors in infiltrating ductal carcinoma of the breast. Boll Soc Ital Biol Sper 66: 135-141, 1990.
26. Elston C. Grading of invasive carcinoma of the breast. In: Diagnostic histopathology of breast. Edinburgh London, Melbourne and New York: Churchill Livingstone; 1987.
27. Romppanen T and Collan Y: Practical guidelines for a morphometric study. Acta Stereol 2: 274-297, 1983.
28. Belkis E, Langhammer H, Sonderhaus G and Bush R: Estrogen and progesterone receptor status in breast carcinoma: correlation with age and histopathology. Turk Cancer 2: 49-53, 1991.
29. Jalava P, Kuopio T, Huovinen R, Laine J and Collan Y: Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cut-off points. Anticancer Res 25: 2535-2542, 2005.
30. Thike AA, Chng MJ, Fook-Chong S and Tan PH: Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 33: 21-25, 2001.
31. Pichon MF, Pallud C, Brunet M and Milgrom E: Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 40: 3357-3360, 1980.
32. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E and Syrjänen K: Hormone receptors as prognostic factors in female breast cancer. Ann Med 23: 643-648, 1991.
33. Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Hietanen T, Aine R and Taskinen PJ: Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res 4: 383-389, 1984.
34. Helin HJ, Helle MJ, Kallioniemi OP and Isola JJ: Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Cancer 63: 1761-1767, 1989.
35. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK and Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 10: 5670-5676, 2004.
36. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E and Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERBB-1- and/or ERBB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808-3816, 2001.
37. Kronqvist P, Collan Y, Kuopio T and Kujari H: Nuclear morphometry in breast cancer: the influence of sampling rules and freezing of samples. Mod Pathol 8: 187-192, 1995.